<DOC>
	<DOCNO>NCT01660334</DOCNO>
	<brief_summary>To collect efficacy safety information voriconazole relate appropriate use daily practice .</brief_summary>
	<brief_title>Voriconazole ( Vfend ) Special Investigation ( Regulatory Post Marketing Commitment Plan )</brief_title>
	<detailed_description />
	<mesh_term>Voriconazole</mesh_term>
	<criteria>Male Female patient prescribed voriconazole ( VFEND ) deep mycosis Scedosporisis . Subject prescribed voriconazole ( VFEND ) deep mycosis Aspergillus , Candidasis , Cryptococcal infection involve Scedosporisis .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Systemic Mycosis</keyword>
	<keyword>Scedosporium infection</keyword>
	<keyword>Scedosporisis</keyword>
	<keyword>Japanese</keyword>
	<keyword>voriconazole</keyword>
	<keyword>VFEND</keyword>
	<keyword>Regulatory Post Marketing Commitment Plan .</keyword>
</DOC>